Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival
rate has shown less than 10% due to its dismal prognosis. To date, the only curative
treatment of pancreatic cancer is surgical resection. However, about 60% of patients with
pancreatic cancer have been diagnosed as a locally advanced unresectable or metastatic
disease at diagnosis owning to its difficulty in the early detection of cancer. The 5-year
survival rate has been reported to be less than 25% even with surgical resection. Considering
the high rate of metastasis and recurrence, systemic chemotherapy is essential to prolong
survival. Therefore, Using AI platforms of RAPTOR (RNA expression-based Anti-symmetrical
Pairing Tool for On-demand Response) and ReDRUG (Restoration using the drug for targeting
unbalanced gene) developed by Oncocross, Chlorphenesin carbamate, and Hydroxychloroquine were
discovered as candidate drugs having anti-metastatic effects.
This study aimed to evaluate the efficacy and safety of hydroxychloroquine and chlorphenesin
carbamate in combination with mFOLFIRINOX in patients with inoperable locally advanced or
metastatic pancreatic cancer.